Clal Biotechnology | CBI - Operating Profit


Clal Biotechnology reported ILS-1.74M in Operating Profit for its fiscal quarter ending in December of 2022.





Operating Profit Change Date
Arca Biopharma USD -25.09M 5.23M Mar/2025
aTyr Pharma USD -26.74M 6.43M Sep/2025
Bio Path USD -3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD -3.09M 100K Mar/2025
Cara Therapeutics USD -2.39M 3.49M Mar/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -7.89M 540K Sep/2025
Immunic USD -25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
RedHill Biopharma USD -4.22M 1.8M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024